Subcutaneous rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, was effective and well tolerated in adults with moderate-to-severe atopic dermatitis (AD), in two phase 3 trials.

“Results from IGNITE and HORIZON support the use of rocatinlimab monotherapy in adult patients with moderate-to-severe atopic dermatitis and the potential for additional benefit of rocatinlimab when combined with ad hoc topical therapy,” the authors wrote. “Safety was consistent with the previous phase 2b study, and rocatinlimab was generally well tolerated, with a low incidence of TEAEs [treatment-emergent adverse events] leading to treatment discontinuation,” they added.

SOURCE:

The study was led by Emma Guttman-Yassky, MD, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, and was published online on November 25, 2025, in The Lancet.

Source: MEDspace